StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BTIG Remains Neutral on Juno Therapeutics (JUNO); Says JCAR015 Will Have 'Limited Impact' on Ests
November 23, 2016 12:15 PM
BTIG affirms Juno Therapeutics Inc. (Nasdaq: JUNO) at Neutral after the company announced that the ROCKET Study had been voluntarily ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
SunTrust Robinson Humphrey Downgrades Juno Therapeutics (JUNO) to Hold
November 25, 2016 6:48 AM
Juno Therapeutics (JUNO) PT Lowered to $34 at Maxim Group
November 23, 2016 1:51 PM
Roth Capital Keeps Lion Bio (LBIO) at 'Buy' Following Juno's (JUNO) ROCKET Study Update
November 23, 2016 11:28 AM
Juno Therapeutics (JUNO) CEO Bishop: Second JCAR015 Patient with Brain Swelling has Died - Conf. call
November 23, 2016 8:44 AM
bluebird bio (BLUE) Falls 5% on Juno Clinical Hold
November 23, 2016 8:42 AM
Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold
November 23, 2016 8:33 AM
Juno Therapeutics (JUNO) to Resume Trading at 8:30AM ET after Clinical Hold Announced
November 23, 2016 8:05 AM
Kite Pharma (KITE) on Watch as Juno Trial Placed on Clinical Hold
November 23, 2016 8:02 AM
Juno Therapeutics (JUNO) Halted for News Release
November 23, 2016 8:01 AM
